首頁 › 腎臟癌(腎細胞癌) › 亞利桑那 › Tucson
Tucson, AZ 的 腎臟癌(腎細胞癌) 臨床試驗
7 項針對 腎臟癌(腎細胞癌) 的研究正在 Tucson(約 30 英里範圍內)及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本(英文)
正在為研究招募對象嗎?將此頁面置頂展示 — $99 / 30 天 →
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
招募中1 期
- University of Arizona Cancer Center, Tucson
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
招募中1 期
- Exelixis Clinical Site #1, Tucson
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
招募中3 期
- Banner University Medical Center - Tucson, Tucson
- University of Arizona Cancer Center-North Campus, Tucson
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
招募中1/2 期
- University of Arizona, Tucson
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
招募中1 期
- University of Arizona, Tucson
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
招募中1 期
- University of Arizona Cancer Center - Tucson /ID# 262698, Tucson
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
招募中3 期
- Banner University Medical Center - Tucson, Tucson
- University of Arizona Cancer Center-North Campus, Tucson
其他城市的 腎臟癌(腎細胞癌) 試驗
- Houston, TX35 項研究
- New York City, NY27 項研究
- Dallas, TX23 項研究
- Nashville, TN23 項研究
- St. Louis, MO23 項研究
- Los Angeles, CA20 項研究
- Boston, MA16 項研究
- Baldwin Park, CA16 項研究
- Pittsburgh, PA15 項研究
- Philadelphia, PA15 項研究
- Queens, NY15 項研究
- Cleveland, OH14 項研究
Tucson 的其他研究
- 乳癌20 項研究
- 肥胖症18 項研究
- 非小細胞肺癌17 項研究
- 過重15 項研究
- 轉移性癌症14 項研究
- 癌症(所有類型)12 項研究
- 心血管疾病12 項研究
- 大腸直腸癌11 項研究
- 前列腺癌11 項研究
- 第二型糖尿病11 項研究
- 脂肪性肝病10 項研究
- 心臟衰竭10 項研究
資料來源:ClinicalTrials.gov,擷取日期 2026年10月6日。各研究自行設定資格標準;由研究團隊決定參與者資格。